JP7614647B2 - １型糖尿病、その他の自己免疫疾患の処置 - Google Patents

１型糖尿病、その他の自己免疫疾患の処置 Download PDF

Info

Publication number
JP7614647B2
JP7614647B2 JP2021536271A JP2021536271A JP7614647B2 JP 7614647 B2 JP7614647 B2 JP 7614647B2 JP 2021536271 A JP2021536271 A JP 2021536271A JP 2021536271 A JP2021536271 A JP 2021536271A JP 7614647 B2 JP7614647 B2 JP 7614647B2
Authority
JP
Japan
Prior art keywords
cells
antibody
seq
antigen
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021536271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515226A (ja
JPWO2020132456A5 (https=
JP2022515226A5 (https=
Inventor
ラヒム ハマド アブデル
ドナー トーマス
アーメド リズワン
オミディアン ザーラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2022515226A publication Critical patent/JP2022515226A/ja
Publication of JPWO2020132456A5 publication Critical patent/JPWO2020132456A5/ja
Publication of JP2022515226A5 publication Critical patent/JP2022515226A5/ja
Application granted granted Critical
Publication of JP7614647B2 publication Critical patent/JP7614647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021536271A 2018-12-20 2019-12-20 １型糖尿病、その他の自己免疫疾患の処置 Active JP7614647B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862782646P 2018-12-20 2018-12-20
US201862782624P 2018-12-20 2018-12-20
US62/782,624 2018-12-20
US62/782,646 2018-12-20
US201962854289P 2019-05-29 2019-05-29
US201962854286P 2019-05-29 2019-05-29
US62/854,289 2019-05-29
US62/854,286 2019-05-29
PCT/US2019/067874 WO2020132456A1 (en) 2018-12-20 2019-12-20 Treating type 1 diabetes, other autoimmune diseases

Publications (4)

Publication Number Publication Date
JP2022515226A JP2022515226A (ja) 2022-02-17
JPWO2020132456A5 JPWO2020132456A5 (https=) 2023-01-11
JP2022515226A5 JP2022515226A5 (https=) 2023-01-11
JP7614647B2 true JP7614647B2 (ja) 2025-01-16

Family

ID=71101601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536271A Active JP7614647B2 (ja) 2018-12-20 2019-12-20 １型糖尿病、その他の自己免疫疾患の処置

Country Status (4)

Country Link
US (1) US20220073963A1 (https=)
EP (1) EP3899039A4 (https=)
JP (1) JP7614647B2 (https=)
WO (1) WO2020132456A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527873A (ja) 2004-03-01 2007-10-04 ペプチミューン，インコーポレイテッド 自己免疫疾患の治療のための方法および組成物
JP2017519970A (ja) 2014-04-22 2017-07-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 自己免疫疾患の診断方法
JP2017205112A (ja) 2010-05-06 2017-11-24 アダプティヴ バイオテクノロジーズ コーポレーション クロノタイププロファイルを用いた健康状態および疾患状態のモニタリング
US20170360931A1 (en) 2014-12-18 2017-12-21 The University Of Chicago Methods and composition for neutralization of influenza

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
JP2010522537A (ja) * 2006-11-30 2010-07-08 ナビジェニクス インコーポレイティド 遺伝子分析系および方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527873A (ja) 2004-03-01 2007-10-04 ペプチミューン，インコーポレイテッド 自己免疫疾患の治療のための方法および組成物
JP2017205112A (ja) 2010-05-06 2017-11-24 アダプティヴ バイオテクノロジーズ コーポレーション クロノタイププロファイルを用いた健康状態および疾患状態のモニタリング
JP2017519970A (ja) 2014-04-22 2017-07-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 自己免疫疾患の診断方法
US20170360931A1 (en) 2014-12-18 2017-12-21 The University Of Chicago Methods and composition for neutralization of influenza

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Diabetes，2015年，Vol.64，pp.172-182

Also Published As

Publication number Publication date
US20220073963A1 (en) 2022-03-10
EP3899039A1 (en) 2021-10-27
EP3899039A4 (en) 2022-09-14
JP2022515226A (ja) 2022-02-17
WO2020132456A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
ES2765874T3 (es) Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
JP2022518925A (ja) 受容体チロシンキナーゼ様オーファン受容体１（ｒｏｒ１）に特異的な抗体およびキメラ抗原受容体
CN120818057A (zh) 靶向共同抗原的抗原结合蛋白
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
KR20200084320A (ko) 공유 항원을 표적으로 하는 항원-결합 단백질
CN112739375B (zh) 靶向共同抗原的抗原结合蛋白
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2018512443A (ja) 抗ｐｖｒｉｇ抗体及び使用方法
JP2021508449A (ja) Ｃｈ３ドメイン中に挿入された特異的ｐｄ−ｌ１結合配列
EP3733705A1 (en) Monoclonal antibodies and methods for using same
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20220115572A (ko) 항-b7-h3 단클론성 항체 및 이의 사용 방법
US20220363752A1 (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP7614647B2 (ja) １型糖尿病、その他の自己免疫疾患の処置
WO2026085531A1 (en) Compositions and methods for treating or preventing type 1 diabetes and other autoimmune diseases
JP2019508415A (ja) 抗シトルリン化ｈｌａポリペプチド抗体及びその使用
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
JPWO2020132456A5 (https=)
Wang Application of Anti-CD3 Immunoglobulins to Study TCR/CD3 Triggering Mechanisms

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241220

R150 Certificate of patent or registration of utility model

Ref document number: 7614647

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150